11 results on '"Almanza, Diego"'
Search Results
2. KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition
- Author
-
Binkley, Michael S, Jeon, Young-Jun, Nesselbush, Monica, Moding, Everett J, Nabet, Barzin Y, Almanza, Diego, Kunder, Christian, Stehr, Henning, Yoo, Christopher H, Rhee, Siyeon, Xiang, Michael, Chabon, Jacob J, Hamilton, Emily, Kurtz, David M, Gojenola, Linda, Owen, Susie Grant, Ko, Ryan B, Shin, June Ho, Maxim, Peter G, Lui, Natalie S, Backhus, Leah M, Berry, Mark F, Shrager, Joseph B, Ramchandran, Kavitha J, Padda, Sukhmani K, Das, Millie, Neal, Joel W, Wakelee, Heather A, Alizadeh, Ash A, Loo, Billy W, and Diehn, Maximilian
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Lung ,Cancer ,Clinical Research ,Lung Cancer ,Biomarkers ,Glutaminase ,Humans ,Kelch-Like ECH-Associated Protein 1 ,Lung Neoplasms ,Mutation ,NF-E2-Related Factor 2 ,Radiation Tolerance ,Biochemistry and cell biology ,Oncology and carcinogenesis - Abstract
Tumor genotyping is not routinely performed in localized non-small cell lung cancer (NSCLC) due to lack of associations of mutations with outcome. Here, we analyze 232 consecutive patients with localized NSCLC and demonstrate that KEAP1 and NFE2L2 mutations are predictive of high rates of local recurrence (LR) after radiotherapy but not surgery. Half of LRs occurred in tumors with KEAP1/NFE2L2 mutations, indicating that they are major molecular drivers of clinical radioresistance. Next, we functionally evaluate KEAP1/NFE2L2 mutations in our radiotherapy cohort and demonstrate that only pathogenic mutations are associated with radioresistance. Furthermore, expression of NFE2L2 target genes does not predict LR, underscoring the utility of tumor genotyping. Finally, we show that glutaminase inhibition preferentially radiosensitizes KEAP1-mutant cells via depletion of glutathione and increased radiation-induced DNA damage. Our findings suggest that genotyping for KEAP1/NFE2L2 mutations could facilitate treatment personalization and provide a potential strategy for overcoming radioresistance conferred by these mutations. SIGNIFICANCE: This study shows that mutations in KEAP1 and NFE2L2 predict for LR after radiotherapy but not surgery in patients with NSCLC. Approximately half of all LRs are associated with these mutations and glutaminase inhibition may allow personalized radiosensitization of KEAP1/NFE2L2-mutant tumors.This article is highlighted in the In This Issue feature, p. 1775.
- Published
- 2020
3. Integrating genomic features for non-invasive early lung cancer detection
- Author
-
Chabon, Jacob J., Hamilton, Emily G., Kurtz, David M., Esfahani, Mohammad S., Moding, Everett J., Stehr, Henning, Schroers-Martin, Joseph, Nabet, Barzin Y., Chen, Binbin, Chaudhuri, Aadel A., Liu, Chih Long, Hui, Angela B., Jin, Michael C., Azad, Tej D., Almanza, Diego, Jeon, Young-Jun, Nesselbush, Monica C., Co Ting Keh, Lyron, Bonilla, Rene F., Yoo, Christopher H., Ko, Ryan B., Chen, Emily L., Merriott, David J., Massion, Pierre P., Mansfield, Aaron S., Jen, Jin, Ren, Hong Z., Lin, Steven H., Costantino, Christina L., Burr, Risa, Tibshirani, Robert, Gambhir, Sanjiv S., Berry, Gerald J., Jensen, Kristin C., West, Robert B., Neal, Joel W., Wakelee, Heather A., Loo, Jr, Billy W., Kunder, Christian A., Leung, Ann N., Lui, Natalie S., Berry, Mark F., Shrager, Joseph B., Nair, Viswam S., Haber, Daniel A., Sequist, Lecia V., Alizadeh, Ash A., and Diehn, Maximilian
- Published
- 2020
- Full Text
- View/download PDF
4. Nonalcoholic Fatty Liver Disease Demonstrates a Pre-fibrotic and Premalignant Molecular Signature
- Author
-
Almanza, Diego, Gharaee-Kermani, Mehrnaz, Zhilin-Roth, Alisa, Rodriguez-Nieves, Jose A., Colaneri, Cory, Riley, Todd, and Macoska, Jill A.
- Published
- 2019
- Full Text
- View/download PDF
5. Caracterización de carbón activado sintetizado a baja temperatura a partir de cáscara de cacao (Theobroma cacao) para la adsorción de amoxicilina
- Author
-
Tejada, Candelaria N., Almanza, Diego, Villabona, Angel, Colpas, Fredy, and Granados, Clemente
- Published
- 2017
6. Characterization of activated carbon synthesized at low temperature from cocoa shell (Theobroma cacao) for adsorbing amoxicillin.
- Author
-
Tejada, Candelaria N., Almanza, Diego, Villabona, Angel, Colpas, Fredy, and Granados, Clemente
- Subjects
- *
ACTIVATED carbon , *LOW temperatures , *CACAO , *AMOXICILLIN , *ZINC chloride , *X-ray diffraction , *AQUEOUS solutions - Abstract
The aim of this research was synthesize and characterize activated carbon obtained at low temperature from cocoa peel (Theobroma cacao), modified with zinc chloride (ZnCl2) for its subsequent use in the removal of amoxicillin. The biomass was characterized by elemental analysis and the activated carbon was characterized by Scanning Electron Microscopy (SEM), X-ray diffraction (XRD), and Surface Area Analysis (BET) in order to determine the chemical composition, morphological and structural characteristics. For the assays of amoxicillin molecular adsorption, was used an aqueous solution of contaminant at 20 ppm, with pH 6 and 9, to which was added 5 g of adsorbent material impregnated with ZnCl2 at 1:3 and 1:4 ratios. These carbons reached surface areas of 287.5 m2/g and 205.4 m2/g, respectively, with average pore sizes from 3 to 4 nm. The percentage of amoxicillin removal was influenced by the pH of the solution to be treated, reaching the highest percentages of adsorption when the pH was acid; removal values achieved for activated carbon 1:3 were 75.4 % and 67.2 %, while for the activated carbon 1:4 were 65.2 % and 56.7 % for solutions at pH 6 and 9, correspondingly. It concludes that the activated carbon obtained at low temperature has potential to remove amoxicillin in aqueous solution and becomes a good alternative due to the availability of the residue. [ABSTRACT FROM AUTHOR]
- Published
- 2017
7. CXCL12/CXCR4 Axis Activation Mediates Prostate Myofibroblast Phenoconversion through Non-Canonical EGFR/MEK/ERK Signaling.
- Author
-
Rodríguez-Nieves, José A., Patalano, Susan C., Almanza, Diego, Gharaee-Kermani, Mehrnaz, and Macoska, Jill A.
- Subjects
MYOFIBROBLASTS ,EPIDERMAL growth factor receptors ,HYPERPLASIA treatment ,BENIGN prostatic hyperplasia ,CHEMOKINE receptors ,CELL differentiation - Abstract
Benign prostate hyperplasia (BPH), an enlargement of the prostate common in aging in men, is associated with urinary voiding dysfunction manifest as Lower Urinary Tract Symptoms (LUTS). Although inflammation and abnormal smooth muscle contractions are known to play key roles in the development of LUTS, tissue fibrosis may also be an important and previously unrecognized contributing factor. Tissue fibrosis arises from the unregulated differentiation of fibroblasts or other precursor cell types into myofibroblasts, which is usually accomplished by activation of the TGFβ/TGFβR axis. Previously we reported that the CXC-type chemokines, CXCL5, CXCL8 and CXCL12, which are up-regulated in the aging in the prostate, can drive this differentiation process as well in the absence of TGFβ. Based on this data we sought to elucidate the molecular mechanisms employed by CXCL12, and its receptor CXCR4, during prostate myofibroblast phenoconversion. The results of these studies suggest that CXCL12/CXCR4-mediated signaling events in prostate myofibroblast phenoconversion may proceed through non-canonical pathways that do not depend on TGFβ/TGFβR axis activation or Smad signaling. Here we report that CXCL12/CXCR4 axis activation promotes signaling through the EGFR and downstream MEK/ERK and PI3K/Akt pathways during myofibroblast phenoconversion, but not through TGFβ/TGFβR and downstream Smad signaling, in prostate fibroblasts undergoing myofibroblast phenoconversion. We document that EGFR transactivation is required for CXCL12-mediated signaling and expression of genes associate with myofibroblast phenoconversion (α-SMA, COL1a1). Our study successfully identified TGFβ/TGFβR-independent molecular mechanisms that promote CXCL12/CXCR4-induced myofibroblast phenoconversion. This information may be crucial for the development of novel therapies and potential biomarkers for prostatic fibrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.
- Author
-
Sulahian, Rita, Kwon, Jason J., Walsh, Katherine H., Pailler, Emma, Bosse, Timothy L., Thaker, Maneesha, Almanza, Diego, Dempster, Joshua M., Pan, Joshua, Piccioni, Federica, Dumont, Nancy, Gonzalez, Alfredo, Rennhack, Jonathan, Nabet, Behnam, Bachman, John A., Goodale, Amy, Lee, Yenarae, Bagul, Mukta, Liao, Rosy, and Navarro, Adrija
- Abstract
The mitogen-activated protein kinase (MAPK) pathway is a critical effector of oncogenic RAS signaling, and MAPK pathway inhibition may be an effective combination treatment strategy. We performed genome-scale loss-of-function CRISPR-Cas9 screens in the presence of a MEK1/2 inhibitor (MEKi) in KRAS- mutant pancreatic and lung cancer cell lines and identified genes that cooperate with MEK inhibition. While we observed heterogeneity in genetic modifiers of MEKi sensitivity across cell lines, several recurrent classes of synthetic lethal vulnerabilities emerged at the pathway level. Multiple members of receptor tyrosine kinase (RTK)-RAS-MAPK pathways scored as sensitizers to MEKi. In particular, we demonstrate that knockout, suppression, or degradation of SHOC2, a positive regulator of MAPK signaling, specifically cooperated with MEK inhibition to impair proliferation in RAS-driven cancer cells. The depletion of SHOC2 disrupted survival pathways triggered by feedback RTK signaling in response to MEK inhibition. Thus, these findings nominate SHOC2 as a potential target for combination therapy. • RTK-RAS-MAPK pathway members score strongly in genome-scale MEKi modifier screens • Depletion of SHOC2 potently sensitizes RAS-driven cells to MEK inhibition • SHOC2 loss impairs RTK-mediated adaptive reactivation of MAPK signaling induced by MEKi • A model of SHOC2 degradation suggests a combination therapeutic strategy with MEKi Sulahian, Kwon, and Walsh et al. performed several loss-of-function CRISPR-Cas9 screens in KRAS -mutant cancer cells treated with a MEK inhibitor and define the landscape of modifiers of MEK inhibitor sensitivity while highlighting that SHOC2 is a potent synthetic lethal target that serves as a critical signaling node to mediate MAP kinase pathway reactivation upon MEK inhibition. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.
- Author
-
Nabet, Barzin Y., Esfahani, Mohammad S., Moding, Everett J., Hamilton, Emily G., Chabon, Jacob J., Rizvi, Hira, Steen, Chloe B., Chaudhuri, Aadel A., Liu, Chih Long, Hui, Angela B., Almanza, Diego, Stehr, Henning, Gojenola, Linda, Bonilla, Rene F., Jin, Michael C., Jeon, Young-Jun, Tseng, Diane, Liu, Cailian, Merghoub, Taha, and Neal, Joel W.
- Subjects
- *
CIRCULATING tumor DNA , *IMMUNE checkpoint inhibitors , *NON-small-cell lung carcinoma - Abstract
Although treatment of non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs) can produce remarkably durable responses, most patients develop early disease progression. Furthermore, initial response assessment by conventional imaging is often unable to identify which patients will achieve durable clinical benefit (DCB). Here, we demonstrate that pre-treatment circulating tumor DNA (ctDNA) and peripheral CD8 T cell levels are independently associated with DCB. We further show that ctDNA dynamics after a single infusion can aid in identification of patients who will achieve DCB. Integrating these determinants, we developed and validated an entirely noninvasive multiparameter assay (DIREct-On, Durable Immunotherapy Response Estimation by immune profiling and ctDNA-On-treatment) that robustly predicts which patients will achieve DCB with higher accuracy than any individual feature. Taken together, these results demonstrate that integrated ctDNA and circulating immune cell profiling can provide accurate, noninvasive, and early forecasting of ultimate outcomes for NSCLC patients receiving ICIs. • Pre-treatment ctDNA features are associated with checkpoint blockade response • Pre-treatment peripheral T cell levels are associated with checkpoint blockade response • Early on-treatment ctDNA dynamics are associated with checkpoint blockade response • Multiparameter noninvasive models can predict checkpoint blockade response in NSCLC Multiparameter noninvasive models that integrate pre-treatment ctDNA and peripheral immune features, together with early on-treatment ctDNA dynamics, show promise in predicting durable clinical response to immune checkpoint blockade treatment in patients with non-small cell lung cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC.
- Author
-
Hellmann MD, Nabet BY, Rizvi H, Chaudhuri AA, Wells DK, Dunphy MPS, Chabon JJ, Liu CL, Hui AB, Arbour KC, Luo J, Preeshagul IR, Moding EJ, Almanza D, Bonilla RF, Sauter JL, Choi H, Tenet M, Abu-Akeel M, Plodkowski AJ, Perez Johnston R, Yoo CH, Ko RB, Stehr H, Gojenola L, Wakelee HA, Padda SK, Neal JW, Chaft JE, Kris MG, Rudin CM, Merghoub T, Li BT, Alizadeh AA, and Diehn M
- Subjects
- Biomarkers, Tumor genetics, Carcinoma, Non-Small-Cell Lung pathology, Circulating Tumor DNA genetics, Disease Progression, Drug-Related Side Effects and Adverse Reactions blood, Drug-Related Side Effects and Adverse Reactions etiology, Follow-Up Studies, Humans, Lung Neoplasms pathology, Prognosis, Antineoplastic Agents, Immunological adverse effects, B7-H1 Antigen antagonists & inhibitors, Biomarkers, Tumor blood, Carcinoma, Non-Small-Cell Lung drug therapy, Circulating Tumor DNA blood, Drug-Related Side Effects and Adverse Reactions diagnosis, Lung Neoplasms drug therapy
- Abstract
Purpose: Treatment with PD-(L)1 blockade can produce remarkably durable responses in patients with non-small cell lung cancer (NSCLC). However, a significant fraction of long-term responders ultimately progress and predictors of late progression are unknown. We hypothesized that circulating tumor DNA (ctDNA) analysis of long-term responders to PD-(L)1 blockade may differentiate those who will achieve ongoing benefit from those at risk of eventual progression., Experimental Design: In patients with advanced NSCLC achieving long-term benefit from PD-(L)1 blockade (progression-free survival ≥ 12 months), plasma was collected at a surveillance timepoint late during/after treatment to interrogate ctDNA by Cancer Personalized Profiling by Deep Sequencing. Tumor tissue was available for 24 patients and was profiled by whole-exome sequencing ( n = 18) or by targeted sequencing ( n = 6)., Results: Thirty-one patients with NSCLC with long-term benefit to PD-(L)1 blockade were identified, and ctDNA was analyzed in surveillance blood samples collected at a median of 26.7 months after initiation of therapy. Nine patients also had baseline plasma samples available, and all had detectable ctDNA prior to therapy initiation. At the surveillance timepoint, 27 patients had undetectable ctDNA and 25 (93%) have remained progression-free; in contrast, all 4 patients with detectable ctDNA eventually progressed [Fisher P < 0.0001; positive predictive value = 1, 95% confidence interval (CI), 0.51-1; negative predictive value = 0.93 (95% CI, 0.80-0.99)]., Conclusions: ctDNA analysis can noninvasively identify minimal residual disease in patients with long-term responses to PD-(L)1 blockade and predict the risk of eventual progression. If validated, ctDNA surveillance may facilitate personalization of the duration of immune checkpoint blockade and enable early intervention in patients at high risk for progression., (©2020 American Association for Cancer Research.)
- Published
- 2020
- Full Text
- View/download PDF
11. CXCL12/CXCR4-Mediated Procollagen Secretion Is Coupled To Cullin-RING Ubiquitin Ligase Activation.
- Author
-
Patalano S, Rodríguez-Nieves J, Colaneri C, Cotellessa J, Almanza D, Zhilin-Roth A, Riley T, and Macoska J
- Subjects
- Adaptor Proteins, Signal Transducing, COP-Coated Vesicles genetics, COP-Coated Vesicles metabolism, Cullin Proteins genetics, Gene Expression Regulation genetics, Humans, Microfilament Proteins genetics, Myofibroblasts metabolism, Procollagen genetics, Receptor, Transforming Growth Factor-beta Type I genetics, Signal Transduction genetics, Transforming Growth Factor beta genetics, Ubiquitin-Protein Ligases genetics, Ubiquitination genetics, Chemokine CXCL12 genetics, Receptors, CXCR4 genetics, Transcriptional Activation genetics, Transcriptome genetics
- Abstract
Tissue fibrosis is mediated by the actions of multiple pro-fibrotic proteins that can induce myofibroblast phenoconversion through diverse signaling pathways coupled predominantly to Smads or MEK/Erk proteins. The TGFβ/TGFβR and CXCL12/CXCR4 axes induce myofibroblast phenoconversion independently through Smads and MEK/Erk proteins, respectively. To investigate these mechanisms at the genetic level, we have now elucidated the TGFβ/TGFβR and CXCL12/CXCR4 transcriptomes in human fibroblasts. These transcriptomes are largely convergent, and up-regulate transcripts encoding proteins known to promote myofibroblast phenoconversion. These studies also revealed a molecular signature unique to CXCL12/CXCR4 axis activation for COPII vesicle formation, ubiquitination, and Golgi/ER localization/targeting. In particular, both CUL3 and KLHL12, key members of the Cullin-RING (CRL) ubiquitin ligase family of proteins involved in procollagen transport from the ER to the Golgi, were highly up-regulated in CXCL12-, but repressed in TGFβ-, treated cells. Up-regulation of CUL3 and KLHL12 was correlated with higher procollagen secretion by CXCL12-treated cells, and this affect was ablated upon treatment with inhibitors specific for CXCR4 or CUL3 and repressed by TGFβ/TGFβR axis activation. The results of these studies show that activation of the CXCL12/CXCR4 axis uniquely facilitates procollagen I secretion through a COPII-vesicle mediated mechanism to promote production of the ECM characteristic of fibrosis.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.